The overarching goal of the Administrative Core is to oversee and coordinate all scientific, regulatory, administrative and fiscal responsibilities of the Program Project grant. The Administrative Core will accomplish its goal through the following specific aims: 1. Ensure integration of all Projects and Cores by managing all oversight strategies, including coordinating the meetings and the External and Internal Advisory Committees and implementing the recommendations of these Committees. 2. Authority to realign resources based upon advice from the External and Internal Advisory Committees in collaboration with the Executive Committee (Program Leaders and Project/Core Leaders). 3. Administer and implement the multiple Principal Investigator Plan. 4. Organize the monthly meetings of the Executive Committee, biannual meeting of Internal Advisory Committee and fri-annual meeting of External Advisory Committee. Organize the POl yearly retreat to assess overall P01 progress, based upon quantitative milestones, and plan and implement next steps making use of the reports from the Internal and External Advisory Committees. 5. Provide fiscal accountability via coordination with Institutional and NCI staff. 6. Document productivity of all Projects and Cores, as defined by discrete endpoints such as manuscripts, filed provisional patent applications, and invited lectures. 7. Prepare all progress reports and responses to External and Internal Advisory Committees. 8. Coordinate and oversee all scientific, regulatory, administrative and fiscal interactions between The John Wayne Cancer Institute, Memorial Sloan-Kettering Cancer Center, Mt Sinai Medical Center, The Jackson Laboratory and Penn State University. 9. Provide oversight management to ensure that biostatistics analyses and plans are implemented for all Projects and Cores. 10. Coordinate Data Sharing modalities between Institutions, NIH, NCL and the public. 11. Coordinate the monthly Core presentations to the Executive Committee that will include description of the active and pending requests for support from each Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA171983-02
Application #
8757122
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Type
DUNS #
City
Hershey
State
PA
Country
United States
Zip Code
17033
Najima, Yuho; Tomizawa-Murasawa, Mariko; Saito, Yoriko et al. (2016) Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood 127:722-34
Morad, Samy A F; Ryan, Terence E; Neufer, P Darrell et al. (2016) Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia. J Lipid Res 57:1231-42
Young, Megan M; Takahashi, Yoshinori; Fox, Todd E et al. (2016) Sphingosine Kinase 1 Cooperates with Autophagy to Maintain Endocytic Membrane Trafficking. Cell Rep 17:1532-1545
Linton, Samuel S; Sherwood, Samantha G; Drews, Kelly C et al. (2016) Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:208-22
Olson, Kristine C; Kulling, Paige M; Olson, Thomas L et al. (2016) Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL Leukemia. Cancer Biol Ther :0
Liu, Qiang; Chen, Longgui; Atkinson, Jennifer M et al. (2016) Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death Dis 7:e2361
Aoki, Yuki; Watanabe, Takashi; Saito, Yoriko et al. (2015) Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood 125:967-80
Hasanali, Zainul S; Saroya, Bikramajit Singh; Stuart, August et al. (2015) Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Sci Transl Med 7:293ra102
Morad, Samy A F; Cabot, Myles C (2015) Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. Biochim Biophys Acta 1851:1134-45
Kester, Mark; Bassler, Jocelyn; Fox, Todd E et al. (2015) Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic. Biol Chem 396:737-47

Showing the most recent 10 out of 18 publications